Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lenalidomide Market
Lenalidomide Market Size
- Report ID: GMI8286
- Published Date: Feb 2024
- Report Format: PDF
Lenalidomide Market Size
Lenalidomide Market size was valued at USD 18 billion in 2023 and is anticipated to register a CAGR of 5.1% between 2024 and 2032. This surge is propelled by various factors, including the escalating prevalence of multiple myeloma worldwide and continuous advancements spurred by research endeavours.
Furthermore, the demand for lenalidomide remains vigorous, buoyed by its proven efficacy in managing multiple myeloma. A report from the American Association for Cancer Research and the National Cancer Institute's Epidemiology and End Results (SEER) program highlights that in 2022, 34,470 individuals in the U.S. were diagnosed with multiple myeloma, underscoring the increasing need for efficacious treatment options.
Lenalidomide is a medication classified as an immunomodulatory agent. It is primarily used in the treatment of certain types of cancer, particularly multiple myeloma, and myelodysplastic syndromes. Lenalidomide works by affecting the immune system and helping to slow down the growth of cancer cells.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Lenalidomide Market Size in 2023: | USD 18 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 5.1% |
| 2024 – 2032 Value Projection: | USD 27.6 Billion |
| Historical Data for: | 2018 – 2023 |
| No. of Pages: | 110 |
| Tables, Charts & Figures: | 200 |
| Segments covered: | Type, Application, End-user, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Lenalidomide Market Scope
